StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report report published on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Marinus Pharmaceuticals Stock Performance
MRNS opened at $0.55 on Thursday. The firm has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $8.94. The firm has a 50-day moving average of $0.55 and a 200 day moving average of $0.70.
Hedge Funds Weigh In On Marinus Pharmaceuticals
Several institutional investors have recently bought and sold shares of MRNS. World Investment Advisors LLC bought a new stake in shares of Marinus Pharmaceuticals in the third quarter valued at $104,000. Virtu Financial LLC purchased a new stake in Marinus Pharmaceuticals in the 4th quarter worth about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $54,000. JPMorgan Chase & Co. lifted its holdings in Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares during the last quarter. Finally, Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals during the fourth quarter worth about $107,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Recommended Stories
- Five stocks we like better than Marinus Pharmaceuticals
- The Most Important Warren Buffett Stock for Investors: His Own
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Consumer Discretionary Stocks Explained
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- Roth IRA Calculator: Calculate Your Potential Returns
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
